BNTX
BioNTech SE
NASDAQ · Healthcare · Biotechnology · DE
$96.06
−2.64%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $0.85
- Revenue estimate
- $1.2B
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$3.70
- EPS estimate
- -$2.40
- Revenue actual
- $120.6M
- Revenue estimate
- $180.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -48.4%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $123
- PT range
- $105 – $136
- Analysts
- 5
4 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$2.40 | -$3.70 | Miss -54.29% | $120.6M |
| May 5, 2026 | -$2.52 | -$2.28 | Beat 9.52% | $136.4M |
| Mar 10, 2026 | -$0.19 | -$0.39 | Miss -103.86% | $1.1B |
| Dec 31, 2024 | — | $1.12 | — | $1.2B |
| Dec 30, 2023 | — | $2.09 | — | $1.6B |
| Dec 31, 2022 | — | $9.97 | — | $4.6B |
| Dec 31, 2021 | — | $14 | — | $6.3B |
| Dec 31, 2020 | — | $1.89 | — | $423.6M |
| Aug 11, 2020 | -$0.29 | -$0.42 | Miss -44.83% | $47.0M |
| Nov 14, 2019 | -$0.21 | -$0.16 | Beat 23.81% | $31.4M |
| Mar 31, 2019 | — | -$0.20 | — | $29.4M |
| Dec 31, 2018 | — | -$0.01 | — | $76.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026